ARTICLES BY ERIN HARRIS
-
Ferring Builds A Global Gene Therapy Manufacturing Network Around ADSTILADRIN5/16/2025
Ferring Pharmaceuticals has built a global manufacturing and support network around its flagship gene therapy, ADSTILADRIN, enabling scalable production, provider education, patient access, and real-world data collection to ensure sustainable and widespread adoption.
-
Atsena Therapeutics Advances Gene Therapy For XLRS5/13/2025
Atsena Therapeutics exemplifies the field’s growing shift toward non-oncology indications with its targeted gene therapy for X-linked retinoschisis, a rare inherited retinal disorder with no approved treatments.
-
Navigating CGT Biotech's Financial Headwinds And The Path Forward4/24/2025
Dr. Ali Pashazadeh, Founder of Treehill Partners shares how CGT companies can navigate today’s biotech downturn by embracing integrated strategies, disciplined capital use, and bold leadership willing to rethink traditional models across innovation, manufacturing, and commercialization.
-
How Cynata Therapeutics is Unlocking the Power of iPSCs to Transform Regenerative Medicine4/11/2025
Cynata Therapeutics is pioneering a scalable, iPSC-based platform to produce consistent, high-quality MSCs that are showing strong clinical promise across multiple indications, including GvHD, diabetic foot ulcers, and osteoarthritis.
-
Emerging Technologies For Cell Therapy Manufacturing4/7/2025
This summary of the Cell & Gene Live, Emerging Technologies in Cell Therapy Manufacturing, explains why automation, robotics, AI, and digital tools offer a clear path to scalable, efficient, and patient-centric manufacturing.
-
Collaboration Leads To CGT Progress At Astellas' West Coast Innovation Center3/13/2025
Yoshi Shitaka, outgoing CSO and Richard Wilson, SVP, Primary Focus Lead (Genetic Regulation) at Astellas share how the company's West Coast Innovation Center serves as a central hub for AI, digital transformation, and more.
-
Tessera Therapeutics Advances In Vivo Gene Therapy For SCD1/30/2025
Tessera Therapeutics' CSO, Michael Holmes, Ph.D., shares information on the company's Gene Writers for sickle cell disease (SCD) and how their work has garnered investment from of the Bill & Melinda Gates Foundation to support their efforts.
-
2025 Outlook For CGT: Focus On Non-Oncology Indications, In Vivo Gene Editing, And POC12/4/2024
Leaders from Kiji Therapeutics, Precision Biosciences, and Orgenesis weigh in on what will likely accelerate the development of novel treatments, potentially revolutionizing patient care across a wider range of diseases and bringing the promise of personalized medicine closer to reality in 2025 and beyond.
-
CD70 & Autoimmune Diseases11/26/2024
Allogene Therapeutics' Dr. Zachary Roberts shares the clinical-stage biotech's rationale behind selecting CD70 as a target for activated T cells in autoimmune diseases.
-
Neogene's Focus On Off-The-Shelf TCR Therapies10/31/2024
This recap of Episode 87 of Cell & Gene: The Podcast shares Neogene Therapeutics' Carsten Linnemann, Ph.D.'s take on why "off-the-shelf" will make t-cell receptor therapies more accessible to patients.